Addresses
We investigated a patient with type 1 diabetes mellitus undergoing pancreatic islets transplantation. In this patient, we evaluated the clinical usefulness of serial measurement of serum S100A8/A9 complex levels for detecting acute inflammatory responses associated with rejection of transplanted pancreatic islets. The serum S100A8/A9 complex was a more sensitive marker for acute inflammation associated with islet transplant rejection than the serum C-reactive protein. Thus, the serial measurement of the serum S100A8/A9 complex concentration is useful for monitoring the patients with pancreatic islet transplantation. 
Case report
A 49-year-old man with type 1 diabetes mellitus (DM) underwent pancreatic islet transplantation at Kyoto University Hospital. Details on medical treatment including insulin injection and immunosuppressants after transplantation have been described elsewhere. 1 In this patient, we have serially measured the serum S100A8/A9 complex levels along with conventional biomarkers. Figure 1 illustrates the postoperative time course of the changes in various biomarkers. Throughout the three months of follow-up period, the serum levels of fasting plasma glucose (FPG), S100A8/A9 complex, C-reactive protein (CRP), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were repeatedly measured. Two prominent peaks of the serum levels of the S100A8/A9 complex were observed until 45 days after transplantation. The second peak was followed by a transient increase in the serum CRP levels, but the ¢rst one was not associated with any change in the CRP levels. In addition, we observed that the recipient had a slight fever during the second peak. These two peaks of the S100A8/A9 complex levels were accompanied by the simultaneous slight increase in all the three liver enzymes, i.e. liver arginase (ARG), AST and ALT. The serum FBS levels were gradually decreased over the follow-up period.
Methods
The serum levels of S100A8/A9 and ARG were measured using two enzyme-linked immunosorbent assay systems developed in our laboratory. 2, 3 The serum concentrations of FPG, CRP, AST and ALT were also measured using conventional methods.
Results and discussion
Pancreatic islets transplantation has been primarily developed to fundamentally cure serious patients with type 1 DM. 4 Two therapeutic approaches for the treatment of the disease have been provided: one is a transplantation of the pancreatic tissue from a braindead or living related donor, the other is pancreatic islet transplantation from them. The latter has recently been noticed as a more sophisticated treatment and is being widely performed. However, some episodes of transplanted islet rejection may lead to acute in£ammatory changes in the liver tissue. It is crucial to detect the pathological changes early, including in£ammation associated with rejection after the islet transplantation.
At present, an available biomarker for monitoring the acute in£ammatory changes associated with rejection is the serum levels of CRP. Recently, we have found that the serum S100A8/A9 complex level serves as a reliable biomarker for detecting acute in£ammatory responses associated with transplant rejection in a patient undergoing small intestine transplantation. 2 The S100A8/A9 complex is an in£ammation-related protein that is produced in several kinds of activated immunological cells, such as neutrophils and macrophages, in acute in£ammatory phase. However, it is still unclear how secretion of the S100A8/A9 complex is regulated. More recently, we have demonstrated that the S100A8/A9 complex is a protein which combines with pro-in£ammatory cytokines, such as tumour necrosis factor-a and interleukin-6, in vitro. 5 We currently consider that this complex may bind non-speci¢cally with these cytokines in vivo to regulate excessive activation of the immunological cells.
We ¢rstly paid attention to signi¢cant increases in serum ARG levels, concomitant with the S100A8/A9 complex. As we reported previously, ARG is a good marker for damage of liver cells, so that some in£ammatory changes may occur in the liver of the recipient, to a greater or lesser extent. 3 However, the marked elevation in the S100A8/A9 complex level is not always associated with rejection after pancreatic islet transplantation. At present, it is di⁄cult to specify pathological changes in the liver of the recipient by means of conventional hepatic markers, such as ARG, AST and ALT. In addition, we are not able to perform biopsy in the recipient liver because the transplanted islet cells di¡use over the recipient liver. It is unclear whether there was any di¡erence in the two occasions with elevated S100A8/A9 levels, so that the true clinical signi¢cance in these peaks is out of our scope. However, we have previously observed the fact that the serum level of the S100A8/A9 complex tends to increase in acute in£ammation associated with rejection after liver and small intestine transplantation. 2 These facts suggest that the signi¢cant increase in the S100A8/A9 complex levels is due to in£ammatory changes associated with rejections after the transplantation. Then, the increase in the S100A8/A9 complex accompanied by the conventional hepatic markers strongly suggests rejection after the transplantation, so that any in£ammatory changes associated with rejection may have occurred in the liver in both situations. Our idea may be supported by the changes in the serum AST and ALT levels which increased a little later or faster than these peaks, together with the S100A8/A9 complex.
No signi¢cant increase in CRP at the ¢rst peak was found. Lipopolysaccharide (LPS) is generally well known as an endotoxin in the liver.When LPS is intraperitoneally administrated in rats, it activates complements in the blood, which are ¢rstly treated and eliminated by the Kup¡er cells (KCs) in the liver. The binding of the activated complements to their speci¢c receptors in the KC results in stimulation of the KCs. Thus, the KCs that are stimulated by the complements produce several cytokines, prostaglandin E 2 and so on in the liver. Consequently, macrophages and neutrophils activated by these substances produce nitric oxide gas and other oxidative substances in the liver. Finally, these substances induce production of CRP in the liver cells. Thus, it is generally believed that it may Figure 1 Postoperative time course of the changes in serum levels of FPG, S100A8/A9, ARG, CRP, AST and ALT take a few days for liver cells to produce CRP in the cells. In the meantime, the S100A8/A9 complex is secreted within 1h after any in£ammatory stimulation. Thus, the S100A8/A9 protein increases in blood earlier than CRP (Figure1). As described above, it is possible that the S100A8/A9 complex non-speci¢cally binds with the pro-in£ammatory cytokines in vivo. This suggests inhibition of stimulation to liver cells by the cytokine network leading to suppression of production of CRP in the liver cells. Therefore, we currently consider that liver cells were not fully activated by these cytokines at the time of the ¢rst peak, so that the production of CRP might be suppressed. At present, an index for the rejection is the plasma FPG level. However, it is not always reliable because insulin injection may conceal the decreased insulin production due to the islets rejection. An alternative diagnostic means is the liver biopsy. The transplanted islets via the portal vein di¡usely lodge in the liver. In£ammation associated with rejection may occur anywhere over the entire liver tissue. Accordingly, the liver biopsy may not be suitable for the detection of islets rejection.
The increase in liver enzymes does not always de¢ne rejection itself. The S100A8/A9 complex is, however, a speci¢c protein that increases markedly in blood of recipients with acute in£ammation associated with organ transplantation. 2 The increase in several hepatic markers, accompanied by the S100A8/A9 complex, suggests rejection in the liver to a greater or lesser extent.We currently consider that the S100A8/A9 complex may be an anti-in£ammatory protein, particularly in acute in£ammatory phase. Then, the S100A8/A9 complex may re£ect the very ¢rst stage of the in£am-mation because the protein is produced in activated macrophages and neutrophils. In view of early detection of acute in£ammatory changes, simultaneous determination of the S100A8/A9 complex and several hepatic markers would give clinical merits for monitoring postoperative conditions of the recipient.
In conclusion, the serial measurement of serum S100A8/A9 complex levels is useful for monitoring patients after pancreatic islet transplantation.
